Boston Scientific Corporation $BSX Stock: Sterling Capital Management LLC Raises Stake

Sterling Capital Management LLC raised its position in Boston Scientific Corporation (NYSE:BSX) by 1,344.7% during the third quarter, HoldingsChannel.com reports. The firm owned 84,691 shares of the medical equipment provider’s stock after purchasing an additional 78,829 shares during the period. Sterling Capital Management LLC’s holdings in Boston Scientific were worth $3,697,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. GraniteShares Advisors LLC boosted its position in shares of Boston Scientific by 1.5% during the first quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock valued at $853,000 after buying an additional 195 shares during the period. Avantax Planning Partners Inc. grew its stake in shares of Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after buying an additional 201 shares during the last quarter. WPG Advisers LLC raised its holdings in shares of Boston Scientific by 11.9% in the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock worth $120,000 after buying an additional 203 shares during the period. Natural Investments LLC raised its holdings in shares of Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after buying an additional 206 shares during the period. Finally, 180 Wealth Advisors LLC raised its holdings in shares of Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after buying an additional 223 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BSX. Leerink Partners dropped their price objective on Boston Scientific from $60.00 to $55.00 in a report on Friday, October 9th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Piper Sandler reduced their target price on Boston Scientific from $65.00 to $60.00 in a research note on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Finally, Truist Financial decreased their target price on Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Price Performance

Shares of BSX stock opened at $45.67 on Friday. The company has a market capitalization of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.10 and a beta of 0.58. The company’s 50-day simple moving average is $45.46 and its two-hundred day simple moving average is $49.16. Boston Scientific Corporation has a one year low of $41.38 and a one year high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.